Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6516
    -0.0020 (-0.31%)
     
  • OIL

    83.00
    +1.65 (+2.03%)
     
  • GOLD

    2,241.90
    +29.20 (+1.32%)
     
  • Bitcoin AUD

    108,690.95
    +3,052.91 (+2.89%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6038
    +0.0007 (+0.12%)
     
  • AUD/NZD

    1.0906
    +0.0026 (+0.24%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

LooK SPOT Antigen Test of 5-8 minutes receives CE-IVD in Europe

LooK SPOT COVID-19 Antigen Rapid Test of 5 to 8 minutes receives CE IVD Clearance for Europe

Laipac Technology Inc.

LooK SPOT COVID-19 Antigen Rapid Test of 5 to 8 minutes receives CE IVD Clearance for Europe
LooK SPOT COVID-19 Antigen Rapid Test of 5 to 8 minutes receives CE IVD Clearance for Europe
LooK SPOT COVID-19 Antigen Rapid Test of 5 to 8 minutes receives CE IVD Clearance for Europe

Richmond Hill, Canada, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Laipac Technology Inc. ("Laipac"), a leader in the development of IoMT (Internet of Medical Things), today announced that their LooK SPOT COVID-19 Antigen Rapid Test received CE IVD clearance for Europe.

The LooK SPOT COVID-19 Antigen Rapid Test is a smartphone-based diagnostic device with lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein from SARS-CoV-2 in nasal swabs from patients suspected of COVID-19 within the first eight (8) days of symptom onset.

ADVERTISEMENT

LooK SPOT COVID-19 Antigen Rapid Test uses the nasal sample collected from 1 inch in the nostril. It uses AI technology to deliver real-time test results within 5 to 8 minutes with 97.4% sensitivity and 98.3% specificity in detecting the SARS-CoV-2 virus. LooK SPOT COVID-19 Antigen Rapid Test can also detect the new variant of the SARS-CoV-2 virus first identified in the UK and South Africa.

"LooK SPOT's AI algorithm has high accuracy and can identify the color signal in low positive cases when human eyes cannot identify. Healthcare responders in Point of Care often need to make time-sensitive decisions to determine the antigen test results when many patients are within their vicinity. But the tempo, volume, stress, fatigue, lighting, fear, and various other factors can overwhelm healthcare responders when making the visual interpretation of antigen test results. LooK SPOT reduces healthcare responders' cognitive load by providing accurate test results in an easy-to-read format. LooK SPOT has been designed with a tactical edge to fight COVID-19." said Diego Lai. Co-Founder and CEO of Laipac.

Patients can download the LooK PASS App from Apple or Google stores to scan the LooK COVID-19 antigen cassette before the test and receive the test results on their phones within 5 to 8 minutes. Negative test results generate a QR code on the app used as a Day Pass to enter the facility or transportation. Laipac also provides API for integration with health & travel applications to control the widespread of the SARS-CoV-2 virus.

About Laipac Technology Inc.

Laipac Technology Inc. is a leading Canadian company in developing the Internet of Medical Things and Telehealth to improve the overall quality of life and save one person at a time. Founded in 1999 by two Canadian entrepreneurs, Maria C. Pacini and Diego Lai, Laipac Technology Inc. currently exports products and solutions worldwide. For more information, visit: www.laipac.com

Media Contact
Company Name: Laipac Technology Inc.
Contact Person: Diego Lai
Email: diego.lai@laipac.com
Address: 20 Mural St. Unit 5
City: Richmond Hill
State: ON
Country: Canada
Website: www.laipac.com


This news has been published for the above source. Laipac Technology Inc. [ID=16496]

Disclaimer: The information does not constitute advice or an offer to buy. Any purchase made from this story is made at your own risk. Consult an expert advisor/health professional before any such purchase. Any purchase made from this link is subject to the final terms and conditions of the website's selling. The content publisher and its distribution partners do not take any responsibility directly or indirectly. If you have any complaints or copyright issues related to this article, kindly contact the company this news is about.

Attachment